Glactone Pharma (Sweden)

Recent papers from Glactone Pharma (Sweden)

1. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironmentJournal of Clinical Investigation · 2019
2. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate CancerScientific Reports · 2018
3. Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate CancerJournal of Medicinal Chemistry · 2016
4. Impact of messages on concomitant use of nicotine replacement therapy and cigarettes: a randomized trial on the InternetAddiction · 2003
5. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practiceAddiction · 2003
6. Multivariate methods in pharmaceutical applicationsJournal of Chemometrics · 2002
7. In vitro test of nicotine's permeability through human skin. Risk evaluation and safety aspectsThe Annals of Occupational Hygiene · 1999
8. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimenThe Prostate · 1999
9. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up   Commentary: Progress on nicotine replacement therapy for smokersBMJ · 1999
10. Comparison of two strategies for assessing ecotoxicological aspects of complex wastewater from a chemical-pharmaceutical plantEnvironmental Toxicology and Chemistry · 1994